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Sgold standard therapy for lung cancer. Future studies are
needed to ascertain the influence of other patient factors
used my experienced thoracic surgeons in determining the
candidacy for lobar resection in patients with marginal
pulmonary reserve.
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Dr Yolonda L. Colson (Boston, Mass). I want to commend you
on a very nice presentation. We have seen several presentations at
this conference that are investigating surgical resection in marginal744 The Journal of Thoracic and Cardiovascular Surgpatients, reflecting how important this topic really is and that we
face it regularly.
I have 3 questions to look at your analysis in more depth.
In the non-marginal group you have almost a 5% incidence of
re-intubation. That seems unusually high. Does it affect the fact
that you say there wasn’t much difference in complications if the
higher incidence of complications was in the non-marginal group?
Among the complications that you did have, did you look at
length of stay, for example, and what the ramifications of those
complications were?
Dr Taylor. Thank you for your questions. There was a
re-intubation rate within the non-marginal pulmonary function
test (PFT) group of approximately 5.3% versus 1.1% in the
marginal PFT group. However, this difference was not
found to be statistically different on univariate analysis. It
is not clear why the non-marginal group had a 4% higher
re-intubation rate. It may be that we are more conservative
in extubating patients with marginal PFTs because of concern
for re-intubation. We did not include length of stay analysis
or specific analysis of the ramifications of postoperative
complications. I think it is important to note that on our
univariate analysis there was a significant difference in a
number of variables, including postoperative myocardial
infarction and acute renal failure. Despite the fact that we
found no significant associations on multivariable analysis,
this data may provide important information about patients
who have marginal PFTs and the need for additional preoper-
ative risk assessment.
Dr Colson. In patients with marginal PFTs, we usually choose
stereotactic body radiotherapy or some other ablative type of
therapy. They tend to think more about quality of life issues or
what the complications are, and that is often the reason that these
therapies will get chosen, more so necessarily than mortality.
In your presentation, we don’t really see afterward what the
functional status is of patients who have had a lobectomy and
how many of them were not receiving oxygen before and then
became oxygen dependent. What is the change that happened
other than just survival and a complication? What happened to
them in terms of their quality of life?
Dr Taylor. That is a great question. I agree that quality of life in
the marginal PFT patient population is quite important. However,
we have not performed quality-of-life assessments on patients
included in this study. That information would be a great follow-up
study.
Dr Colson. We know if you do a lobectomy on a patient
who has an upper lobe with a large bullous emphysema or a
middle lobectomy it is very different than doing a lower
lobectomy on somebody who has significant perfusion to that
lobe, and I don’t see that broken out here. Can you characterize
what characteristics in these marginal patients allow safe
resection? Who did well and didn’t do well in terms of what their
disease looked like?
Dr Taylor. Looking at the demographics of the population,
there was no difference in the proportion of upper lobectomy to
lower lobectomy when comparing marginal group to nonmarginal
group. We did not perform a subgroup analysis to determine, for
example, what factors are important for a good outcome in patients
with marginal PFTs who underwent lower lobectomy. This is aery c February 2014
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be important to consider in patients with marginal PFTS who
need resection.
Dr Colson. Is it possible that what we are really looking at is
that these results confirm the ability of a surgeon to look at
marginal PFTs and decide when they are not as marginal as we
think?
Dr Taylor. That is a great point. Pulmonary function tests are
only 1 factor in considering if a patient is eligible for resection
and it is clear that a thorough evaluation of the entire clinical
picture is essential when considering lobectomy in this patient
population.
Dr Thomas A. D’Amico (Durham, NC). I enjoyed your
presentation, Dr Taylor.
What percentage of the patients underwent thoracoscopic
lobectomy?
Dr Taylor. Thoracoscopic lobectomy represented 20% of the
procedures performed.
DrD’Amico.Did you not put that in your risk model, whether it
was a thoracoscopic or open lobectomy?
Dr Taylor. Given the small proportion of patients undergoing
video-assisted thoracoscopic lobectomy, we did not include it.
We did do a subgroup analysis that is not included in the results
reported here and we did not find any significant difference
between video-assisted thoracoscopic surgery and the open
technique with regard to morbidity and mortality in patients with
marginal PFTs. Now, if that is a reflection of our sample size
and the fact that we have significantly fewer patients who
underwent video-assisted thoracoscopic surgical procedures than
open, that may be the case.
Dr D’Amico. Do you have any idea what percentage had
pulmonary hypertension?
Dr Taylor. I do not have the percentage of patients within
the study who have pulmonary hypertension. I believe that is
1 of the limitations of this study. Not having pulmonary
hypertension data limits some of the inclusion criteria within the
clinical trial.
Dr K. Robert Shen (Rochester, Minn). I enjoyed your
presentation very much and I think it is a very timely analysis.
One of the things that all thoracic surgeons do when
evaluating if patients with marginal pulmonary function can
tolerate surgery is to factor in other things that we inherently
know will affect that patient’s risk profile. Although there isn’t
much prospective data to prove that getting current smokers to
stop smoking for a period of time before surgery and putting
them through a preoperative pulmonary rehabilitation program
has a positive effect in getting a patient with marginal PFT
through an operation safely, I am more inclined in that patient
compared with a patient with good PFT, to say, ‘‘I’m not going
to offer you surgery until you stop smoking and go through
pulmonary rehab.’’ Did you put into your risk model any
information about whether or not those patients in the
marginal group were treated differently in terms of things like
that—requiring them to stop smoking, putting them through
rehab—and does the data allow you to address any of those
issues? I think they are quite important and we are
lacking data to show if those things may be helpful in these
patients.The Journal of Thoracic and CaDr Taylor.We did not include those particular variables within
our analysis. There are data that suggest that pulmonary rehab is
effective for increasing exercise capacity, but there is some
question as to whether there is any increase in actual PFT
improvement. I agree that evaluating the effect of smoking
cessation and the use of pulmonary rehab on patients with
marginal PFTs may uncover another variable that may be
important in risk stratifying this patient population.
Dr Raphael Bueno (Boston, Mass). Do you have 90-day
mortality data? Particularly for these kinds of patients, we ought
to start reporting 90-day mortality.
Dr Taylor. In the non-marginal group, our 90-day mortality was
2.6% and in the marginal group it was 3.8%.
Dr Bueno. So that is substantially up from 30-day mortality.
Dr Taylor. That is correct. It was not statistically significant on
univariate analysis.
Dr Bueno. So, again, reinforcing the need to answer that
question.
Dr Thomas K.Waddell (Toronto, Ontario, Canada). I enjoyed
your presentation.
I am convinced by your data that the current criteria by which
these trials have been constructed are not good predictors. I think
that is pretty obvious. The question is if there are better predictors.
I think there are 2 subsets of things you should consider. How
many patients went on to stereotactic body radiation therapy and
what did their profile look like by these same measures; that is,
do you actually just use a lower threshold of the same measures,
or are you not measuring to these criteria and not based on the
right measure? I am interested in to what extent these marginal
candidates had mixed venous partial pressure of oxygen
measurements, forced vital capacity measurements to really
determine that forced expiratory volume in 1 second below a
certain level is actually an obstructive physiology, and quantitative
ventilation/perfusion lung scan, so just in general, the use of
ancillary measures to more precisely refine your patient selection.
Dr Taylor. Thank you Dr Waddell for these important
questions. Although we did not include the profile of patients
undergoing stereotactic body radiation therapy within our
institution in this study, I believe your point is critical and a
comparison that needs to be evaluated. With regard to our use
of ancillary measures to further define pulmonary function
(ie, quantitative perfusion scan and mixed venous partial pressure
of oxygen), our algorithm is that if a patient has an forced
expiratory volume in 1 second or carbon monoxide diffusing
capacity<50%, then we proceed with a quantitative perfusion
scan. If that is<40%, then we will proceed with an mixed venous
partial pressure of oxygen study. If it is>15, we consider them
eligible for resection. If the value is between 10 and 15, it is a
discussion between all parties involved, including the medical
oncologists and the surgeons. Because not all patients in study
had mixed venous partial pressure of oxygen or perfusion scans,
we calculated predicted postoperative pulmonary function by
quantifying the number of bronchopulmonary segments resected
to use the same methodology on all patients.
Dr Frank A. Baciewicz (Detroit, Mich). I have 1 quick
comment.
We recently studied a cohort of patients with forced expiratory
volume in 1 second around 1 L. We gave them several weeks ofrdiovascular Surgery c Volume 147, Number 2 745
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Spulmonary therapy and found that you can slightly improve the
forced expiratory volume in 1 second. You don’t improve it
significantly and it doesn’t change their outcomes. This is data
we are publishing in the future.
I agree that the criteria mentioned do not define high-risk
patients. I was curious about patient outcomes if you subdivided746 The Journal of Thoracic and Cardiovascular Surgthem into patients who were receiving home oxygen or who had
forced expiratory volume in 1 second of 1 or<1.
Dr Taylor. We did not perform a subgroup analysis by
stratifying forced expiratory volume in 1 second of 1 or <1.
However, the use of preoperative oxygen therapy was not found
to be an independent predictor of death or major morbidity.ery c February 2014
